Vergelijking
Exenatide vs. Lixisenatide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
141758-74-9
320367-13-3
Molecuulmassa
4186.6 g/mol
4858.5 g/mol
Halfwaardetijd
2.4 h
3 h
Sequentie
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Werkingsmechanisme
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
5
5
waarvan bij mensen
4
5
Geregistreerde effecten
3
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
2
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Exenatide and Lixisenatide?
- Exenatide is classified as "Metabool", while Lixisenatide is classified as "Metabool". Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Exenatide or Lixisenatide?
- The highest available evidence level is "Humane RCT" for Exenatide and "Humane RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Exenatide and Lixisenatide in Germany and the United States?
- Duitsland: Exenatide — Op recept, Lixisenatide — Op recept. Verenigde Staten: Exenatide — Op recept, Lixisenatide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.